Skip to main content
SpringerLink
Log in

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindered. Alternative strategies for the investigation of new agents in patients with GCT should be considered, particularly when studying the efficacy and relative toxicity of platinum analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee FH, Canetta R, Issell BF, Lanaz L: New platinum complexes in clinical trials. Cancer Treat Rep 10:29–51, 1983

    Google Scholar 

  2. Creaven PJ, Madajewica S, Pendyala L, Mittleman A, Pontes E, Spaulding M, Arback S, Soloman J: Phase I Clinical Trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep 67:795–800, 1983

    Google Scholar 

  3. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  4. Drasga RE, Williams SD, Einhorn LH, Birch R: Phase II Evaluation of iproplatin in refractory germ cell tumors: a Southwestern Cancer Study Group Trial. Cancer Treat Rep 71:863–864, 1987

    Google Scholar 

  5. Claven M, Monfardini S, Siegenthaler P, Pinedo HM, Renard J: Phase II trial of CHIP in previously treated disseminated testicular cancer. Proc ASCO 5:108, 1986

    Google Scholar 

  6. Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Herr H, Morse M, Fair W, Pramod S, Russo P, Bosl GJ: The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476–2481, 1990

    Google Scholar 

  7. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550–556, 1992

    Google Scholar 

  8. Motzer R, Geller N, Tan C, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G: Salvage chemotherapy for patients with germ cell tumors. Cancer 67:1305–1310, 1991

    Google Scholar 

  9. Motzer RJ, Bosl GJ, Tauer K, Golbey R: Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 71:197–198, 1987

    Google Scholar 

  10. O'Reilly SM, Rustin GJS, Smith DB, Newlands ES: Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumors. Annals of Oncology 3:1992 (in press)

  11. Pederson AG, Bork E, Osterling K, Dombernowsky P, Hanson H: Phase II study of teniposide in small cell carcinoma of the lung. Cancer Treat Rep 68:1289–1291, 1984

    Google Scholar 

  12. Bork E, Hansen M, Dombernowsky P, Hansen S, Pederson AG, Hansen HH: Teniposide (VM-26) an overlooked highly active agent in small-cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 4:524–527, 1986

    Google Scholar 

  13. Evans WK, Eisenhauer EA, Cormier Y, Wierzbicki R, Laberge F, Shepherd FA: Phase II Study of Amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8:390–395, 1990

    Google Scholar 

  14. Holmes AF, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805, 1991

    Google Scholar 

  15. Ettinger DS, Finkelstein DM, Abeloff MD, Bonomi PD: Justification for evaluating new anticancer drugs in selected untreated patients with a chemotherapy-sensitive advanced cancer: an ECOG randomized trial. Proc ASCO 9:864, 1990

    Google Scholar 

  16. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis A: Single-agent chemotherapy trials in small-cell lung cancer, 1970–1990: the case for studies in previously treated patients. J Clin Oncol 10:484–498, 1992

    Google Scholar 

  17. Nichols C, Saxman S, Williams S, Loehrer PJ, Miller ME, Wright C, Einhorn LH: Primary mediastinal nonsemenomatous germ cell tumors — a modern single institution experience. Cancer 65:1641–1646, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Barbara A. Murphy, Robert J. Motzer & George J. Bosl

Authors
  1. Barbara A. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George J. Bosl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, B.A., Motzer, R.J. & Bosl, G.J. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs 10, 327–330 (1992). https://doi.org/10.1007/BF00944190

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00944190

Key words

Search

Navigation